Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	: ME	MBER'S FIRST NAME: _	
that is important for the rev	ut all applicable sections com view (e.g., chart notes or lab o rotected Health Information u	data, to support the authoriz	any additional documentation zation request). Information
			☐ URGENT
MEMBER INFORMATIO	N		
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:			
CITY:		STATE: ZIP (	CODE:
PATIENT INSURANCE I	D NUMBER:		
MALE FEMALE	HEIGHT (IN/CM): W	/EIGHT (LB/KG):	ALLERGIES:
FOLLOWING LINK: PRIM PATIENT'S AUTHORIZED AUTHORIZED REPRESE	ZATION FORM WITH THIS F IETHERAPEUTICS.COM/NO D REPRESENTATIVE (IF AP NTATIVE'S PHONE NUMBE	<u>PPP</u> PLICABLE):	
PRESCRIBER INFORMA	ATION	EIDOT MANE	
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:			
CITY:		STATE: ZIP	CODE:
REQUESTER (if different than prescriber):		OFFICE CONTACT PERSON:	
MEDICATION OF MEDI		ATION .	
MEDICATION OR MEDIC MEDICATION NAME:	CAL DISPENSING INFORMA	ATION	
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
☐ NEW THERAPY		NEWAL: DATE THERAPY	INITIATED:
DURATION OF THERAP	Y (SPECIFIC DATES):		

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.15.2025



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

WEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
ext page					
		CONDITION?			
THERAPY UG NAME AND	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
NOSES:		ICD-10:			
nosis:	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Is patient going to be using drug in combination with a clinical trial?   Yes No  Is prescriber one of the below?  Yes No: Hematologist/oncologist  Gastroenteroloist  Hepatologist  Will patient use in combination with Promacta(eltrombopag), Nplate(romiplostim), Tavalisse(fostamatinib), and/or Wayrilz(rilzabrutinib)?  Yes No					
going to have one o	f the helesy precedures 2 - Vec -	No. Places sixele and			
paracentesis thoracentesis gastrointestinal endo liver biopsy bronchoscopy ethanol ablation thera chemoembolization vascular catheterizati transjugular intrahepa dental procedure renal biopsy biliary intervention nephrostomy tube pla radiofrequency ablati	scopy apy on atic portosystemic shunt acement				
	ATIENT TRIED ANY complete below)  /THERAPY UG NAME AND  NOSES: er disease undergoing hrombocytopenia (ITP) nosis:  / CLINICAL INFORMATA PRIOR AUTHORIZING to be using drug in the below?  ist/oncologist   Gas se in combination with chronic liver disease in combination with chronic li	ATIENT TRIED ANY OTHER MEDICATIONS FOR THIS complete below)  DO    NO			

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.15.2025



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:	
Is patient's chronic liver disease Model for End-stage liver disease(MELD) score $\leq$ 24? $\Box$ Yes $\Box$ No Please submit chart documentation.	l
Is patient's thrombocytopenia mean baseline platelet count less than 50,000? $\square$ Yes $\square$ No <i>Please submit chart documentation</i> .	
For patient's with idiopathic thrombocytopenia(ITP): For INITIAL Request of immune (idiopathic) thrombocytopenic purpura (ITP), answer the following Is Promacta prescribed by a hematology/oncology specialist?   Yes  No	j:
Is the patient's platelet count less than 30,000/mcL OR greater than or equal to 30,000/mcL with additional risk factors for bleeding? $\square$ Yes $\square$ No *Please submit documentation.	
Please submit with chart notes the exact month and year that patient was diagnosed with immune (idiopathic) thrombocytopenic purpura (ITP)	
For newly diagnosed primary ITP, is the request within 3 months since the initial date of diagnosis $\hfill \square$ Yes $\hfill \square$ No	;?
For persistent primary ITP, is the request 3 to 12 months since the initial date of diagnosis? $\hdots$ No	
For chronic ITP, is the request greater than or equal to 12 months since the initial diagnosis? $\hdots$ No	S 🗆
Have all other causes of secondary ITP been ruled out such as: Inherited thrombocytopenia, Myelodysplastic Syndrome, HIV, HCV, CLL, drug-induced immune thrombocytopenia, SLE, RA, common variable immune deficiency (CVID), Helicobacter pylori infection, CMV, selective IgA deficiency, autoimmune lymphoproliferative syndrome (ALPS)? □ Yes □ No	
Has the patient had an insufficient response, intolerance or or absolute contraindication to corticosteroids?* $\Box$ Yes $\Box$ No *Please submit documentation.	
Has the patient had an insufficient response, intolerance or or absolute contraindication to immunoglobulins (IVIG)?* □ Yes □ No *Please submit documentation.	
Has the patient had an insufficient response, intolerance or absolute contraindication to rituximab $\Box$ Yes $\Box$ No *Please submit documentation.	?*
Has the patient had an insufficient response, intolerance or absolute contraindication to Nplate(romiplostim)?* □ Yes □ No *Please submit documentation.	
Has the patient had an insufficient response, intolerance or absolute contraindication to eltrombopag(Promacta)?* □ Yes □ No *Please submit documentation.	



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
Has the patient had a splenectomy with an inadequate response? □ Yes □ No
If patient has had a splenectomry, has the patient had an insufficient response or intolerance to post-splenectomy corticosteroids?* □ Yes □ No *Please submit documentation.
If patient has had a splenectomry, has the patient had an insufficient response or intolerance to post-splenectomy IVIG?* □ Yes □ No *Please submit documentation.
If patient has had a splenectomry, has the patient had an insufficient response or intolerance to post-splenectomy eltrombopag(Promacta)?* □ Yes □ No *Please submit documentation.
For patients over 61 years of age, do the results from the most recent bone marrow aspiration show evidence of myelodysplasia as a possible cause for thrombocytopenia?* $\Box$ Yes $\Box$ No *Please submit documentation.
For <u>RENEWAL</u> Request of <u>immune (idiopathic) thrombocytopenic purpura (ITP):</u> Is patient continuing to have a positive clinical response?   — Yes — No *Please submit documentation.
Has the patient had a splenectomy with an inadequate response? □ Yes □ No If "no" to the above question, does the patient have an absolute contraindication to splenectomy?*□ Yes □ No *Please submit documentation which includes surgeon or anesthesiologist consultation.
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
<b>Please note:</b> Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification: Date:
<b>CONFIDENTIALITY NOTICE:</b> The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return EAX) and arrange for the return or destruction of these documents.



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

